Biohaven flunks Alzheimer’s phase 2/3, touts failed subgroup as sign of efficacy

A phase 2/3 clinical trial of Biohaven Pharmaceutical’s troriluzole in Alzheimer’s disease has missed its co-primary endpoints. Biohaven, which slipped the news out on a federal holiday, is yet to quit on the program, though, pointing to a “nonsignificant numerical difference of a potential benefit” in a 97-subject subgroup to argue troriluzole may have a future in the indication.

Ideaya, Spelman College team up to provide young African American women a steppingstone to biotech careers

When the Biotechnology Innovation Organization (BIO) surveyed its member companies last year, it found they were approaching gender parity but were lagging behind on racial and ethnic diversity. Spelman College and Ideaya Biosciences are taking aim at both through a partnership that will connect the former’s students with internships and other opportunities from the latter.

Lantern Pharma Announces Pricing of $60 Million Public Offering

DALLAS — Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 per share, for gross proceeds of $60 million, before deducting underwriting discounts and offering expenses. In addition, Lantern Pharma has granted the underwriters a 45-day option to purchase up to an additional 642,856 shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments. All of the shares of common stock are being offered by Lantern Pharma.

Marizyme Announces Approval for DuraGraft® in India

JUPITER, Fla.,– Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft® is now registered and licensed for import into India through Marizyme’s distribution partner Regency Lifesciences.

error: Content is protected !!